The U.S. Food and Drug Administration (FDA) has approved Pfizer's PENBRAYA, a vaccine for the prevention of the five most common serogroups causing meningococcal disease in adolescents. The vaccine provides the broadest serogroup coverage of any meningococcal vaccine available in the U.S. and could simplify the complex vaccination schedule. The approval is based on data from Phase 2 and Phase 3 trials, demonstrating robust immunogenicity and a favorable safety profile.